AMRI piles on profits with strong Q1

AMRI's ($AMRI) days of posting quarterly net losses appear to be far behind, as the company rode an 11% revenue jump to $6.5 million in net income, up from a negative $3.8 million in the same period last year.

Total revenue came in at $59.4 million in the second quarter, fueled mostly by a 9% increase in contract sales, which reached $46.5 million. Within that unit, discovery services grew 13% to $11 million, while AMRI's booming large-scale manufacturing business grew 14% to $26.4 million. Small-scale contract revenue decreased 7% to $9.1 million on the quarter, a drop AMRI said was within its expectations.

Royalty revenue came in at $12.9 million, driven by AMRI's share of sales from Sanofi's ($SNY) Allegra and Actavis' ($ACT) amphetamine salts.

For the full year, AMRI is still expecting revenue of up to $213 million, which would be a 12% leap over 2012.

"Our overall performance for the first quarter of 2013 reaffirms the consistent and positive direction of our company," CEO Thomas D'Ambra said in a statement. "We continue to build global relationships to drive value for our shareholders, as evidenced by the recently signed agreements with Ono Pharmaceutical for drug discovery and development services and a specialty pharmaceutical company for various services for multiple oncology products."

The Ono deal, good for 5 years, follows AMRI's weighty re-signing with GE Healthcare ($GE), its largest supply client, and launch of a collaboration with Codexis ($CDXS) to pool resources on API manufacturing. The company has also inked recent partnerships with Knopp Biosciences and Shire ($SHPG).

- read AMRI's full results

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.